BBIO Stock Price History and Quote Analysis Insights for Investors
BridgeBio Pharma, Inc.
Stock Price Today
BridgeBio Pharma, Inc. (BBIO) stock declined over -1.62%, trading at $26.66 on NASDAQ, down from the previous close of $27.10. The stock opened at $26.77, fluctuating between $26.36 and $27.23 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Company Information
| Employees | 550 |
| Beta | 1.09 |
| Sales or Revenue | $9.30M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
BridgeBio Pharma, Inc. (NASDAQ: BBIO) stock price is $26.66 in the last trading session. During the trading session, BBIO stock reached the peak price of $27.23 while $26.36 was the lowest point it dropped to. The percentage change in BBIO stock occurred in the recent session was -1.62% while the dollar amount for the price change in BBIO stock was -$0.44.
The NASDAQ listed BBIO is part of Biotechnology industry that operates in the broader Healthcare sector. BridgeBio Pharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Eric Michael David J.D., M.D., Ph.D.
Chief Executive Officer of Gene Therapy
Dr. Brian C. Stephenson C.F.A., Ph.D.
Chief Financial Officer & Sec.
Dr. Neil Kumar Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. Charles J. Homcy M.D.
Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Dr. Richard H. Scheller Ph.D.
Chairman of R&D
Grace Rauh
Vice President of Communications
Mr. Eli M. Wallace Ph.D.
Chief Scientific Officer of Oncology
Dr. Thomas Trimarchi Ph.D.
Chief Product Officer
Dr. Uma Sinha Ph.D.
Chief Scientific Officer
Dr. Frank McCormick Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Dr. Frank P. McCormick Ph.D.
Scientific Founder & Member of Scientific Advisory Board
BBIO's closing price is 23.31% higher than its 52-week low of $21.62 where as its distance from 52-week high of $44.32 is -39.85%.
Number of BBIO employees currently stands at 550.
Official Website of BBIO is: https://www.bridgebio.com
BBIO could be contacted at phone 650 391 9740 and can also be accessed through its website. BBIO operates from 421 Kipling Street, Palo Alto, CA 94301, United States.
BBIO stock volume for the day was 1.11M shares. The average number of BBIO shares traded daily for last 3 months was 2.13M.
The market value of BBIO currently stands at $5.04B with its latest stock price at $26.66 and 188.99M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com